Table 1.

Demographic and baseline characteristics

Characteristics	Eculizumab naive (part 2) IV loading doses on day 1 (375 mg), day 8 (500 mg), day 22 (1000 mg); 170 mg s.c. weekly starting on day 29 (N = 10)	Switched to crovalimab (part 3)
		Group A: IV loading dose (1000 mg), followed by 680 mg s.c. every 4 wk* (n = 7)	Group B: IV loading dose (1000 mg), followed by 340 mg s.c. every 2 wk (n = 6)	Group C: IV loading dose (1000 mg), followed by 170 mg s.c. weekly (n = 6)	All (N = 19)
Age, mean ± SD, y	53.9 ± 11.8	48.9 ± 4.8	53.2 ± 13.7	46.5 ± 13.7	49.5 ± 11.0
Sex
Female	4 (40)	4 (57.1)	0	2 (33.3)	6 (31.6)
Male	6 (60)	3 (42.9)	6 (100)	4 (66.7)	13 (68.4)
Race
Asian	3 (30)	2 (28.6)	2 (33.3)	3 (50.0)	7 (36.8)
White	7 (70)	4 (57.1)	3 (50.0)	2 (33.3)	9 (47.4)
Unknown	0	1 (14.3)	1 (16.7)	1 (16.7)	3 (15.8)
Weight, mean ± SD, kg	75.35 ± 15.98	88.27 ± 28.36	85.67 ± 26.17	65.03 ± 19.65	80.11 ± 26.03
C5 polymorphism	1 (10)	0	0	1 (17)	1 (6)
Granulocyte clone size, mean ± SD	80 ± 18	92 ± 8	84 ± 18	80 ± 13	86 ± 13
Baseline LDH,† mean ± SD, U/L	1159 ± 608	230 ± 46	415 ± 256	353 ± 323	327 ± 233
Baseline hemoglobin, mean ± SD, g/L	95.2 ± 14.7	106.4 ± 14.7	94.8 ± 8.3	112.5 ± 24.5	104.7 ± 17.7
Eculizumab dose regimen before switch
Labeled dose (900 mg every 2 wk)	NA	5 (71)	4 (67)	6 (100)	15 (79)
Higher dose or higher frequency (1200 mg every 2 wk)	NA	2 (29)	2 (33)	0 (0)	4 (21)
Patients with RBC transfusion in past 12 mo	3 (30)	3 (43)	3 (50)	2 (33)	8 (42)
RBC units transfused in past 12 mo, n	6	22	30	4	56

Unless otherwise noted, all data are n (%).

NA, not applicable; s.c., subcutaneously; SD, standard deviation.

^*After the first 2 patients, the treatment regimen was modified to 170 mg weekly for the first 8 wk of subcutaneous dosing.

^†Upper limit of normal, 210 U/L.